The phase III PACIFIC trial (NCT02125461) demonstrated a robust overall survival benefit of continued PD-L1 inhibitor durvalumab administration, as a consolidation treatment after chemoradiation for patients with unresectable stage III NSCLC [54]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.